Skip to content
Subscriber Only

Lilly Profit Falls Short as Humalog Insulin Sales Disappoint

  • Third time in four quarters that earnings lower than expected
  • Cialis, Humalog, Jardiance revenue misses analysts’ estimates
Video player cover image

Eli Lilly CEO: We're Pleased With Our 3Q Performance

Updated on

Eli Lilly & Co. posted third-quarter profit that missed analysts’ predictions after disappointing sales from both its best-selling treatment, the blockbuster Humalog insulin, and newer products like diabetes pill Jardiance.

Earnings excluding some items were 88 cents a share, the company said Tuesday in a statement, compared with the 96-cent average of estimates compiled by Bloomberg.